Evaluierung von Vorhersageparametern zum Vorhandensein eines Residualtumors im Rahmen einer transurethralen Nachresektion der Harnblase bei nicht muskelinvasiven Urothelkarzinomen - Ergebnisse einer universitären Ausbildungsklinik

Das Karzinom der Harnblase stellt das fünfthäufigste Malignom der westlichen Welt, sowie den zweithäufigsten bösartigen Tumor der ableitenden Harnwege nach dem Prostatakarzinom, dar [7, 127]. Mit 70 bis 85% machen die oberflächlichen Läsionen den Großteil dieser Erkrankung aus [7, 34, 37, 66, 127]....

Full description

Saved in:
Bibliographic Details
Main Author: Hartinger, Jeremias
Contributors: Hegele, A. (Prof. Dr.) (Thesis advisor)
Format: Dissertation
Language:German
Published: Philipps-Universität Marburg 2012
Operative Medizin
Subjects:
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!

1. Trivedi D and Messing EM: Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol 2009;9.


2. Simon J et al.: Intravesikale Therapie beim nicht muskelinvasiven Urothelkarzinom der Harnblase. Der Urologe 2009;48:1263-1272.


3. Sievert KD et al.: Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295-300.


4. Sheweita SA et al.: Effects of Schistosoma haematobium infection on drug-metabolizing enzymes in human bladder cancer tissues. Cancer Lett 2004;205:15-21.


5. Unsal A et al.: The diagnostic efficiency of ultrasound guided imaging algorithm in evaluation of patients with hematuria. Eur J Radiol 2009;79:7-11.


6. 125. van der Meijden AP et al.: EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48:363-371.


7. van Rhijn BW et al.: Recurrence and progression of disease in non- muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-42.


8. Richardson SD et al.: Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection by-products in drinking water: a review and roadmap for research. Mutat Res 2007;636:178-242.


9. Schips L et al.: Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220- 223.


10. van der Meijden AP et al.: Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito- Urinary Group Phase III Trial. Eur Urol 2003;44:429-434.


11. Villanueva CM et al.: Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. Am J Epidemiol 2007;165:148-156.


12. Vegt PD et al.: Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 1997;157:1246-1249.


13. Shirodkar SP and Lokeshwar VB: Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 2009;19:488-493.


14. Schwaibold HE et al.: The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:1199-1201.


15. Stoehr B et al.: Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C. BJU Int 2008;102:1556-1559.


16. Skinner DG et al.: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-467.


17. Sylvester RJ, Oosterlinck W and van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186- 2190.


18. Stenzl A et al.: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815-825.


19. Tran E et al.: Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol 2009;32:333-337.


20. Vaishampayan U: Systemic therapy of advanced urothelial cancer. Curr Treat Options Oncol 2009;10:256-266.


21. Wirth M and Hakenberg O: Urologie im Rahmen der onkologischen Chirurgie in Praxis der Viszeralchirurgie 2006. Siewert JR, Rothmund M and Schumpelick V, Editors. Springer Berlin Heidelberg. p. 819-829.


22. Resel Folkersma LE et al.: Complications of endovesical treatment with BCG in a series of 200 patients. Arch Esp Urol 1999;52:957-965.


23. Stenzl A et al.: EAU guidelines on muscle-invasive and metastatic urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.


24. Solsona E et al.: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999;161:1120-1123.


25. Suttmann H et al.: Gibt es eine Indikation für eine adjuvante oder neoadjuvante Systemtherapie beim Blasenkarzinom? Der Urologe 2007;46:1379-1384.


26. Sylvester RJ, van der MA and Lamm DL: Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.


27. van der Meijden AP et al.: Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito- urinary group randomized phase III trial. J Urol 2001;166:476-481.


28. Witjes JA and Hendricksen K: Intravesical pharmacotherapy for non- muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008;53:45- 52.


29. Sylvester RJ et al.: Long-Term Efficacy Results of EORTC Genito- Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2009;57:766-773.


30. Roberts JT et al.: Long-term survival results of a randomized trial comparing gemcitabine / cisplatin and methotrexate / vinblastine / doxorubicin / cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;17:118-22.


31. Powles T et al.: Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-1521.


32. Vale CL: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202-206.


33. Sylvester RJ et al.: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-477.


34. Sternberg CN et al.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-407.


35. Vogeli TA et al.: Prospective study of effectiveness. Reoperation (re- TUR) in superficial bladder carcinoma. Urologe A 2002;41:470-474.


36. Stein JP et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666- 675.


37. Yafi FA and Kassouf W: Role of lymphadenectomy for invasive bladder cancer. Can Urol Assoc J 2009;3:206-210.


38. von Knobloch R et al.: Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001;94:67-72.


39. Retz M, Gschwend JE and Lehmann J: Systemic chemotherapy for bladder cancer: news in 2009. Urologe A 2009;48:655-662.


40. Zurkirchen MA et al.: Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int 2004;72:99-102.


41. Stockle M et al.: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52.


42. Sternberg CN et al.: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007;69:62-79.


43. Pectasides D, Pectasides M and Nikolaou M: Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 2005;48:60-68.